Synovics Pharmaceuticals, Inc. (SYVC)
Synovics Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Fort Lauderdale, FL, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,983. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -15.4%. Its beta of 169.69 implies it has historically moved more than the broad market.
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company’s OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
Synovics Pharmaceuticals, Inc. is most often compared with the following Healthcare names: